Home / Infectious Diseases

Infectious Diseases

FDA Grants Breakthrough Therapy Designation to Eiger’s Treatment for Hepatitis Delta Virus Infection

PALO ALTO, Calif., Aug. 20, 2019 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for peginterferon lambda (Lambda) for the treatment of hepatitis …

Read More »

Nabriva’s Xenleta Receives FDA Approval for Treatment of Community-Acquired Bacterial Pneumonia

DUBLIN, Ireland, Aug. 19, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the U.S. Food and Drug Administration (FDA) has approved Nabriva’s new drug applications for the oral and …

Read More »

FDA Approves Breakthrough Drug to Treat Extensively Drug-Resistant Tuberculosis

RESEARCH TRIANGLE PARK, N.C., Aug. 14, 2019 /PRNewswire/ — Today, the Food and Drug Administration (FDA) announced its approval of pretomanid, a new drug developed to treat Extensively Drug-Resistant Tuberculosis (XDR-TB) and treatment intolerant/non-responsive Multidrug-Resistant (MDR) TB. RTI International (RTI) scientist Dr. Doris Rouse and her team have collaborated closely …

Read More »

FDA Grants Qualified Infectious Disease Product Designation to Daré Bioscience’s DARE-BV1 for Treatment of BV in Women

SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that DARE-BV1, a novel thermosetting hydrogel containing clindamycin phosphate 2%, has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration (FDA) for the treatment …

Read More »

Roche Expands Global Access Program Beyond HIV to Include Diagnostic Tests for Tuberculosis, Hepatitis and HPV

Basel, 22 July 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs where the disease burden is the …

Read More »

AbCellera and Gilead Enter Infectious Disease Therapeutic Antibody Discovery Collaboration

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera, a leader in therapeutic antibody discovery from natural immune systems, today announced it has entered into an agreement with Gilead Sciences to support the discovery of therapeutic antibody candidates for infectious diseases. AbCellera will apply its expertise in single-cell screening of natural immune sources to generate …

Read More »

FDA Approves Merck’s Zerbaxa 3g Dose for the Treatment of Adults with Hospital-Acquired Pneumonia

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Merck’s supplemental New Drug Application (sNDA) for the use of ZERBAXA® (ceftolozane and tazobactam) for the treatment of patients 18 years and older with hospital-acquired bacterial …

Read More »

FDA Grants Breakthrough Therapy Designation to La Jolla Pharmaceutical’s Investigational Treatment for Severe Malaria

SAN DIEGO, April 24, 2019 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for …

Read More »

Bayer’s Phase 3 Trial Of Nifurtimox in Pediatric Patients with Chagas Disease Meets Primary Endpoint

WHIPPANY, N.J., March 14, 2019 /PRNewswire/ — Bayer presented results today from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinical study of investigational nifurtimox in pediatric patients with Chagas disease at the “XV Taller sobre la enfermedad de Chagas” conference in Barcelona, Spain. …

Read More »

AbCellera Signs Agreement with Global Health Foundation to Fight Infectious Disease

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera today announced a two-year agreement with the Bill & Melinda Gates Foundation to help accelerate global health research. The funding, totaling $4.8 M, will support a series of scientific collaborations between AbCellera and Gates Foundation-funded scientists working on the prevention and treatment of high-priority infectious diseases. The …

Read More »